News | May 06, 2023
Ajanta pharma posts Q4FY23 consolidated PAT at Rs. 122.25 Cr
The company has reported total income of Rs. 918.67 crores during the period ended March 31, 2023
The company has reported total income of Rs. 918.67 crores during the period ended March 31, 2023
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Specialty Chemicals grew 38% YoY for FY23
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
The company has reported total income of Rs. 691.9 crores during the quarter ended December 31, 2022
The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.
The vaccine is under FDA review
Revenues from operations for the full year ended March 31, 2022 stood at Rs. 590.05 crore as compared to Rs. 449.82 crore in FY21
Subscribe To Our Newsletter & Stay Updated
